Should a serum 25-hydroxyvitamin D level be obtained in the acute evaluation of a patient presenting with stroke symptoms?

Vitamin D Testing in Acute Stroke: Not Indicated

Routine measurement of serum 25-hydroxyvitamin D levels is not indicated during the acute evaluation of stroke symptoms and should not be part of the initial diagnostic workup.

Guideline-Based Recommendations

The 2013 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke explicitly outline essential laboratory tests for acute stroke evaluation, and vitamin D testing is notably absent from this list 1. The guideline emphasizes that:

• Only essential diagnostic tests should be performed before acute treatment decisions
• Tests that are time-consuming and may delay emergency treatment should be deferred
• The priority is completing evaluation and initiating fibrinolytic treatment within 60 minutes of ED arrival

The recommended acute laboratory panel includes: CBC with platelets, electrolytes, renal function, glucose, cardiac biomarkers, coagulation studies (PT/INR, aPTT), and lipid profile 1. Additional tests like chest radiography are only performed when clinically indicated (e.g., suspected pulmonary disease), not routinely.

The 2024 Endocrine Society Clinical Practice Guideline on vitamin D similarly does not recommend routine 25(OH)D testing for disease prevention in general populations, reinforcing that vitamin D measurement should be reserved for established clinical indications, not acute stroke presentations 2.

Clinical Context and Timing Considerations

The acute stroke window demands rapid assessment focused on treatment eligibility, not prognostic biomarkers. Every minute of delay increases disability risk. While research demonstrates associations between low vitamin D levels and stroke severity 3, 4, 5, these findings reflect:

• Prognostic information, not actionable acute management decisions
• Chronic nutritional status, which cannot be corrected acutely
• Observational associations, not established causal relationships requiring immediate intervention

When Vitamin D Assessment May Be Appropriate

If vitamin D measurement has any role in stroke care, it belongs in the post-acute or secondary prevention phase, not during the hyperacute evaluation. Consider checking 25(OH)D levels:

• During rehabilitation hospitalization for risk stratification
• As part of comprehensive vascular risk factor assessment after stabilization
• When planning long-term secondary stroke prevention strategies
• In patients with multiple vascular risk factors during outpatient follow-up

Common Pitfalls to Avoid

1. Do not delay rtPA or thrombectomy to obtain vitamin D levels—there is no therapeutic intervention that would change based on this result in the acute setting
2. Do not confuse prognostic biomarkers with diagnostic necessities—many factors predict outcomes but aren't required for acute decision-making
3. Do not order tests that cannot influence immediate management—vitamin D supplementation, even if deficiency is found, has no role in acute stroke treatment

The Evidence Landscape

While multiple recent studies show correlations between low 25(OH)D and worse stroke outcomes 3, 4, 5, 6, 7, 8, including a 2026 study demonstrating associations with inflammatory markers and disability scores 3, none of these investigations suggest that measuring vitamin D acutely changes management or improves outcomes. The research consistently identifies vitamin D as a prognostic marker rather than a therapeutic target in the acute phase.

Focus acute stroke evaluation on time-sensitive, treatment-altering diagnostics as outlined in established guidelines, reserving vitamin D assessment for the appropriate post-acute setting if clinically warranted.